Genentech, a member of the Roche Group (RHHBY), announced the FDA has approved a label extension for Evrysdi to include babies under two months old with spinal muscular atrophy. Evrysdi is now approved to treat spinal muscular atrophy in children and adults of all ages.
The company noted that, as part of the label extension, the Evrysdi prescribing information has been updated to include recent two-year pooled data from parts 1 and 2 of the FIREFISH study, which showed long-term efficacy and safety in symptomatic infants with Type 1 SMA.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.